Funding the next wave of biopharma innovation

Our firm

We operate at the intersection of science, medicine and investing

We are the world’s largest buyer of biopharmaceutical royalties and a leading funder of innovation in life sciences.

Learn more
#1
Buyer of biopharma royalties
>$30bn
Announced transactions since founding
>80
Royalty acquisitions since founding

Partners

Partner with us

We are the leading partner funding innovation in life sciences with more than 60% global market share. Our unique capabilities to provide tailored funding solutions and customize win-win partnerships have positioned us as the partner of choice in the biopharma ecosystem.

Learn more about our investment approach

Our investment approach film

Investors

Inaugural Investor Day

Royalty Pharma Investor Day highlights stronger growth outlook and the power of its unique business model to do drive value for all stakeholders.

Royalty Pharma

News

Latest developments

Responsibility

Creating value for stakeholders

We create value for our stakeholders by funding innovation across the life sciences ecosystem. Our policies and practices are designed to minimize our sustainability-related risk and uphold our commitments to our stakeholders and partners.

Learn more

Accelerating Bio-Innovation

At the leading edge of life sciences

Held in partnership with the University of Cambridge and the Massachusetts Institute of Technology since 2019, the Accelerating Bio-Innovation Conference is an interdisciplinary summit that brings to light the triumphs and hurdles in drug discovery and development. The event brings together thought leaders from the bio-innovation sphere to engage in crucial debates and discussions confronting pioneers in the world of new biopharmaceuticals, bridging the realms of science, investing and innovative therapeutics.

Find out more
Accelerating Bio-Innovation 2024

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe